medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»medalphabet-287Research ArticleСтатьиВопросы рационального выбора нестероидных противовоспалительных препаратов при сердечно-сосудистом рискеRational use of nonsteroidal anti-inflammatory drugs in cardiovascular riskЛаринаВ. Н.LarinaV. N.noemail@neicon.ruЧукаеваИ. И.ChukaevaI. I.noemail@neicon.ruФГБОУ ВО «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Минздрава РоссииРоссияRussian National Research Medical University n.a. N. I. PirogovRussian Federation201703112017234Современная поликлиника613Copyright © Ларина В.Н., Чукаева И.И., 20172017Ларина В.Н., Чукаева И.И.Larina V.N., Chukaeva I.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/287

Статья посвящена актуальной проблеме лечения болевого синдрома при остеоартрозе у лиц пожилого возраста. Приводятся современные сведения о механизме действия, эффективности, преимуществах и недостатках нестероидных противовоспалительных препаратов в клинической практике. Особое внимание уделяется умеренно селективному ингибитору циклооксигеназы-2 (ЦОГ-2) мелоксикаму. Показано, что прием мелоксикама ассоциируется с небольшим риском развития осложнений со стороны сердечно-сосудистой системы и желудочно-кишечного тракта, что делает возможным осторожное применение этого препарата у лиц старшего возраста с сочетанной патологией.

The rewiew is dedicated to the actual problem of treatment of pain syndrome in elderly patients with arterial hypertension and osteoarthritis. The article describes the mechanism of action, effectiveness, specific advantages and disadvantages of non-steroidal anti-inflammatory drugs. Clinical data on semiselective cyclooxygenase-2 (COX-2) inhibitor meloxicam are discussed. The cardiovascular and gastrointenstunal safety of meloxicam has been shown in elderly multimorbidity paitients.

нестероидные противовоспалительные препаратымелоксикампожилые больныеартериальная гипертензияостеоартритnon-steroidal anti-inflammatory drugsmeloxicamelderly patientsarterial hypertensionosteoarthritisReferencesLalić J., Radovanović R., Mitić B., Nikolić V., Spasić A., Koraćević C. Medication adherence in outpatients with arterial hypertension. Acta Facultatis Medicae Naissensis 2013; 30 (4): 209-218.Lalić J., Radovanović R., Mitić B., Nikolić V., Spasić A., Koraćević C. Medication adherence in outpatients with arterial hypertension. Acta Facultatis Medicae Naissensis 2013; 30 (4): 209-218.Goltz L., Kullak-Ublick G., Kirch W. Potentially inappropriate prescribing for elderly outpatients in Germany: a retrospective claims data analysis. Int. J. Clin Pharmacol Ther 2012; 50 (3): 185-194.Goltz L., Kullak-Ublick G., Kirch W. Potentially inappropriate prescribing for elderly outpatients in Germany: a retrospective claims data analysis. Int. J. Clin Pharmacol Ther 2012; 50 (3): 185-194.Ferrah N., Lovell J., Ibrahim J. Systematic review of the prevalence of medication errors resulting in hospitalization and death of nursing home residents. J Am Geriatr Soc 2017; 65: 433-442.Ferrah N., Lovell J., Ibrahim J. Systematic review of the prevalence of medication errors resulting in hospitalization and death of nursing home residents. J Am Geriatr Soc 2017; 65: 433-442.ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2013; 31: 1281-1357.ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2013; 31: 1281-1357.Чазова И. Е. и соавт. Диагностика и лечение артериальной гипертонии. Клинические рекомендации/ МЗ РФ., Москва, 2013.65 с.Чазова И. Е. и соавт. Диагностика и лечение артериальной гипертонии. Клинические рекомендации/ МЗ РФ., Москва, 2013.65 с.Общероссийская общественная организация «Ассоциация ревматологов России». Федеральные клинические рекомендации по диагностике и лечению остеоартроза, 2013.Общероссийская общественная организация «Ассоциация ревматологов России». Федеральные клинические рекомендации по диагностике и лечению остеоартроза, 2013.Musumeci G., Aiello F., Szychlinska M. et al. Osteoarthritis in the XXIst Century: Risk Factors and Behaviours that Influence Disease Onset and Progression Int J Mol Sci2015; 16 (3): 6093-6112.Musumeci G., Aiello F., Szychlinska M. et al. Osteoarthritis in the XXIst Century: Risk Factors and Behaviours that Influence Disease Onset and Progression Int J Mol Sci2015; 16 (3): 6093-6112.Наумов А. В., Алексеева Л. И., Верткин А. Л. Ведение больных с остеоартритом и коморбидностью в общей врачебной практике. Клинические рекомендации консенсуса экспертов в Российской Федерации. Москва 2015.Наумов А. В., Алексеева Л. И., Верткин А. Л. Ведение больных с остеоартритом и коморбидностью в общей врачебной практике. Клинические рекомендации консенсуса экспертов в Российской Федерации. Москва 2015.Chuang P., Shen S., Yang T. et al. Non-steroidal anti-inflammatory drugs and the risk of a second hip fracture: a propensity-score matching study. BMC Musculoskeletal Disorders 2016; 17: 201.Chuang P., Shen S., Yang T. et al. Non-steroidal anti-inflammatory drugs and the risk of a second hip fracture: a propensity-score matching study. BMC Musculoskeletal Disorders 2016; 17: 201.Каратеев А. Е., Насонов Е. Л., Яхно Н. Н. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология 2015; (1): 4-23.Каратеев А. Е., Насонов Е. Л., Яхно Н. Н. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология 2015; (1): 4-23.Schmidt M., Lamberts M., Olsen A. et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J 2016; 37 (13): 1015-1023.Schmidt M., Lamberts M., Olsen A. et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J 2016; 37 (13): 1015-1023.Алексеева Л.И, Коваленко П. С. Мелоксикам в ревматологической практике: история применения в терапии боли. Современная ревматология 2016; 2: 50-55.Алексеева Л.И, Коваленко П. С. Мелоксикам в ревматологической практике: история применения в терапии боли. Современная ревматология 2016; 2: 50-55.FitzGerald G., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433-442.FitzGerald G., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433-442.Grosser T., Fries S., FitzGerald G. Biological basis for the cardiovascular conse- quences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116:4-15.Grosser T., Fries S., FitzGerald G. Biological basis for the cardiovascular conse- quences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116:4-15.Blaha N., Emberson J., Merhi A. et al. Vascular and upper gastrointenstinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomized trials. Coxib and traditional NSAID Trailists’ (CNT) Collaboration. Lancet 2013; 382 (9894): 769-779.Blaha N., Emberson J., Merhi A. et al. Vascular and upper gastrointenstinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomized trials. Coxib and traditional NSAID Trailists’ (CNT) Collaboration. Lancet 2013; 382 (9894): 769-779.Каратеев А. Е., Насонов Е. Л., Новикова Д. С. Новые данные по безопасности НПВП: Представление о «класс-специфическом» высоком кардиоваскулярном риске селективных ингибиторов ЦОГ-2 устарело. Терапия 2017; 2 (12): 101-107.Каратеев А. Е., Насонов Е. Л., Новикова Д. С. Новые данные по безопасности НПВП: Представление о «класс-специфическом» высоком кардиоваскулярном риске селективных ингибиторов ЦОГ-2 устарело. Терапия 2017; 2 (12): 101-107.Rainsford K. Anti-inflammotary drugsin the 21scentury. Subcell Biochem 2007; 42:3-27.Rainsford K. Anti-inflammotary drugsin the 21scentury. Subcell Biochem 2007; 42:3-27.US Food and Drug Administration. Analysis and recommendations for agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. http://www. fda.gov/Drugs/DrugSafety/PostmarketDrug-SafetyInformationforPatientsandProviders/.US Food and Drug Administration. Analysis and recommendations for agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. http://www. fda.gov/Drugs/DrugSafety/PostmarketDrug-SafetyInformationforPatientsandProviders/.Thomas D., Ali Z., Zacharian S. et al. Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs. Am J Cardiovasc Drugs 2017.Thomas D., Ali Z., Zacharian S. et al. Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs. Am J Cardiovasc Drugs 2017.Kumar B., Swee M. Nonsteroidal Anti-inflammatory Drug Use in a Patient With Hypertension: A Teachable Moment. JAMA Intern Med 2015; 175 (6): 892-3.Kumar B., Swee M. Nonsteroidal Anti-inflammatory Drug Use in a Patient With Hypertension: A Teachable Moment. JAMA Intern Med 2015; 175 (6): 892-3.Schreudering A., De Smet P., Buurma H. et al. NSAID-antihypertensive drug interactions: Which outpatients are at risk for a rise in systolic blood pressure? European Journal of Preventive Cardiology 2013; 1 (22): 91-99.Schreudering A., De Smet P., Buurma H. et al. NSAID-antihypertensive drug interactions: Which outpatients are at risk for a rise in systolic blood pressure? European Journal of Preventive Cardiology 2013; 1 (22): 91-99.Patrono C. Cardiovascular effects of non-steroidal anti-inflammatory dtugs. Cur Cardiol Rep 2016; 18: 25.Patrono C. Cardiovascular effects of non-steroidal anti-inflammatory dtugs. Cur Cardiol Rep 2016; 18: 25.Capone M., Tacconelli S., Di Francesco L., Sacchetti A., Sciulli M., Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 2007; 82: 85-94.Capone M., Tacconelli S., Di Francesco L., Sacchetti A., Sciulli M., Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 2007; 82: 85-94.Moodley I. Review of the cardiovascular safety of COXIBs compared to NSAIDSCardiovasc J Afr 2008; 19: 102-107.Moodley I. Review of the cardiovascular safety of COXIBs compared to NSAIDSCardiovasc J Afr 2008; 19: 102-107.Blot I., Marcelis A., Devogelaer J., Manicourt D. Effects of diclofenac, aceclofenac and meloxicam on proteoglycans and hyaluronan in ostheoarhtritic human cartilage. Br J Pharmacol 2000; 7 (131): 1413-1421.Blot I., Marcelis A., Devogelaer J., Manicourt D. Effects of diclofenac, aceclofenac and meloxicam on proteoglycans and hyaluronan in ostheoarhtritic human cartilage. Br J Pharmacol 2000; 7 (131): 1413-1421.Furst D., Kolba K., Fleischmann R. et al. Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac. J Rheumatol 2002; 29 (3): 436-46.Furst D., Kolba K., Fleischmann R. et al. Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac. J Rheumatol 2002; 29 (3): 436-46.Chen Y., Jobanputra P., Barton P. et al. Cy-clooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technology Assessment 2008; 1211: 1-298.Chen Y., Jobanputra P., Barton P. et al. Cy-clooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technology Assessment 2008; 1211: 1-298.Singh G, Lanes S, Triadafilopoulos S. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am J Med 2004; 117 (2): 100-106.Singh G, Lanes S, Triadafilopoulos S. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am J Med 2004; 117 (2): 100-106.Singh G., Graham D., Wang H. et al. Concominant aspirin use reduces the risk of acute myocardial infarction in users of cy-clooxygenase-2 selective and some non-selective nonsteroidal anti-inflammatory drugs. Ann Rheum Dis 2006; 65 (Suppl. II): 61 (OP0024 abst).Singh G., Graham D., Wang H. et al. Concominant aspirin use reduces the risk of acute myocardial infarction in users of cy-clooxygenase-2 selective and some non-selective nonsteroidal anti-inflammatory drugs. Ann Rheum Dis 2006; 65 (Suppl. II): 61 (OP0024 abst).Asghar W., JamaliF. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology 2015; 23 (1): 1-16.Asghar W., JamaliF. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology 2015; 23 (1): 1-16.Hassan M., El-Beshbishy H., Aly H. et al. Modulatory effects of meloxicam on cardiotoxicity and antitumor activity of doxorubicin in mice. Cancer Chemother Pharmacol 2014; 74 (3): 559-69.Hassan M., El-Beshbishy H., Aly H. et al. Modulatory effects of meloxicam on cardiotoxicity and antitumor activity of doxorubicin in mice. Cancer Chemother Pharmacol 2014; 74 (3): 559-69.Gunter B., Butler K., Wallace R. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis. Journal of Clinical Pharmacy and Therapeutics 2017; 42, 27-38.Gunter B., Butler K., Wallace R. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis. Journal of Clinical Pharmacy and Therapeutics 2017; 42, 27-38.

The authors declare that there are no conflicts of interest present.